Katya

Ethinylestradiol and Gestodene, the active ingredients in Katya, are a combined oral contraceptive presented as a tablet for oral use. They work together to prevent pregnancy in women of reproductive age by inhibiting ovulation, thickening cervical mucus, and altering the endometrial lining.

GNH USA supplies Katya as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory support for global distribution. This enables reliable access to the medication across diverse healthcare settings.

Katya, a combined oral contraceptive, acts on the hypothalamic‑pituitary‑ovarian axis to prevent pregnancy. - Contraception: provides reliable prevention of unintended pregnancy in women of childbearing potential. - Menstrual cycle regulation: helps achieve more predictable menstrual bleeding patterns. - Ovarian cyst reduction: may reduce the incidence of functional ovarian cysts associated with the menstrual cycle.

Katya may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset, often transient. - Headache: tension‑type or migraine‑like pain. - Breast tenderness: swelling or discomfort of the breasts. - Breakthrough bleeding: spotting between periods.

Serious or Rare Side Effects: - Venous thromboembolism: deep vein thrombosis or pulmonary embolism. - Hepatic adenoma: benign liver tumor, rare but reported. - Hypertensive crisis: sudden severe increase in blood pressure.

Before prescribing Katya, clinicians should consider several precautionary measures to ensure safe use. - Contraindications: avoid in women with a history of thromboembolic disorders, active liver disease, or known estrogen‑dependent tumors. - Smoking: do not use in patients over 35 who smoke, due to increased cardiovascular risk. - Cardiovascular risk: assess for hypertension, hyperlipidaemia, or coronary artery disease before initiation. - Medication review: evaluate concurrent use of drugs that may increase clotting risk, such as certain antiretrovirals or hormonal therapies. - Pregnancy and lactation: discontinue if pregnancy is confirmed; not recommended during breastfeeding without medical guidance. - Store at ambient temperature: keep tablets below 25 °C in the original packaging, protected from moisture and light.

Katya can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Anticoagulants: may reduce effectiveness of warfarin, requiring close INR monitoring. - Enzyme inducers: rifampicin, carbamazepine, and phenytoin can lower hormone levels, risking contraceptive failure. - Antifungal agents: ketoconazole and itraconazole may increase hormone concentrations, raising side‑effect risk.

Moderate Interactions (Monitor Closely): - Antidepressants: St. John’s wort can modestly reduce contraceptive efficacy. - Antiretrovirals: protease inhibitors may increase hormone levels, necessitating monitoring. - Diuretics: may affect fluid balance and blood pressure when combined with estrogen.